US FDA approves AbbVie's rare blood cancer drug
The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell neoplasm, a very rare type of blood cancer.
Open original sourceLoading market dashboard